Skip to content

Clinical study of ultrasound-guided neuromodulation in the treatment of post-traumatic complex regional pain syndrome (type II)

Efficacy and safety of ultrasound-guided lumbar sympathetic pulse radiofrequency in the treatment of post-traumatic complex regional pain syndrome (type II): a randomized controlled study

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000037755
Enrollment
Unknown
Registered
2020-09-04
Start date
2020-09-01
Completion date
Unknown
Last updated
2020-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complex regional pain syndrome (type II)

Interventions

lumbar sympathetic block group:lumbar sympathetic block
lumbar sympathetic pulse radiofrequency group:lumbar sympathetic pulse radiofrequency

Sponsors

Shanghai Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. For those patients who were diagnosed according to IASP criteria for CRPS (type II), the pain was mainly located in one lower limb; 2. Patients with VAS score of 4-10; 3. Patients with a course of disease from 3 months to 20 years; 4. The patients who are conscious, have no mental disorder, have no severe gravity, liver and kidney diseases, can cooperate with the examination and tolerate the treatment of sympathetic nerve puncture.

Exclusion criteria

Exclusion criteria: 1. Patients who do not meet the above diagnostic criteria; 3. Patients with unclear consciousness and unable to cooperate with relevant examinations and tolerate neuromodulation therapy; 4. Patients with systemic or local active infection; 5. Patients with severe cardiopulmonary disease; 6. Patients with severe liver and kidney dysfunction; 7. Patients with coagulation dysfunction; 8. Patients with mental disorders; 9. Pregnant and lactating patients; 10. Patients with communication disorders; 11. Patients who are allergic to hormones or local anesthetics.

Design outcomes

Primary

MeasureTime frame
visual analogue pain scale;Cerebral functional magnetic resonance;

Secondary

MeasureTime frame
Inflammatory cytokines;Cytoimmune factor;leptin;

Countries

China

Contacts

Public ContactXu Yongming

Shanghai Sixth People's Hospital

dr.suresh@163.com+86 18621833337

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 11, 2026